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www.sciencedirect.comEDITORIAL‘‘Booby-Trap’’ – Dental implants at bayBisphosphonates are used widely in the management of bone
diseases including osteoporosis, Paget’s disease and hypercal-
cemia related to malignancy. Bisphosphonates inhibit osteo-
clast mediated bone resorption, and therefore contribute to
an increase in bone mineral density. They have also been
shown to inhibit tumor cell proliferation and inhibit angiogen-
esis. These added features have made bisphosphonates useful
in the management of bone metastases. Several clinical trials
have shown that bisphosphonates reduce skeletal tumor
burden in patients with multiple myeloma, breast cancer and
prostate cancer, leading to an increase in the use of bisphos-
phonates in the management of metastatic disease.
Incidents of osteonecrosis of the jaw have been reported in
people using bisphosphonates and undergoing invasive dental
treatment procedures, including tooth extractions, dental im-
plants, and surgical and nonsurgical periodontal treatment.
However, the rate of occurrence of this complication, and
the factors that predispose to its occurrence are not well under-
stood. A true cause-and-effect relationship between osteone-
crosis of the jaw and bisphosphonate use has not yet been
established.
There is also an incomplete understanding of how bis-
phosphonate therapy may affect tissue healing and the success
rate of dental implants. The risk for bisphosphonate-induced
osteonecrosis may be inﬂuenced by the route of administration
of the drug, the potency and the duration of use. Jaw osteone-
crosis appears more associated with the intravenous use of bis-
phosphonates. A review showed that 94% of the published
cases of osteonecrosis had been treated with intravenous,
nitrogen-containing bisphosphonates. Furthermore, a retro-
spective study found that 10% of patients treated with intrave-
nous bisphosphonates developed osteonecrosis. On the other
hand, the risk for osteonecrosis seems low in users of oral bis-
phosphonates. Although most of the complications following
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Production and hosting by Elsevierby dental surgery or dental trauma, some cases may develop
osteonecrosis without a history of preceding dental procedure.
Bisphosphonate-mediated inhibition of osteoclast function
seems to decrease bone resorption and inhibit normal bone
remodeling. Bone resorption and remodeling play an essential
role in maintaining normal bone homeostasis. As osteoclasis
occurs, cytokines and growth factors are released into sur-
rounding matrix essential for modulating new bone develop-
ment. Bisphosphonates may alter bone homeostasis and
there by the ability of bone to heal after minor insults is com-
promised. The bone may also become secondarily infected and
sequestrate, leading to a lesion that appears clinically similar to
osteoradionecrosis. Pathogenesis of the osteonecrotic process
is most consistent with localised vascular insufﬁciency. This
is believed to be important in reducing tumor burden by
depriving tumor cells of adequate nutrients and blood supply.
However, if osteoclastic function is too severely impaired,
osteocytes are not replaced and the capillary network in the
bone is not maintained, resulting in avascular bone necrosis.
Presently, there is no effective treatment for the condition.
Surgical intervention tends to expose further bone and locating
viable bone margins is problematic. Covering exposed bone
with tissue ﬂaps is ineffective because of development of ﬁstu-
lae around the ﬂaps. As osteonecrosis and its complications
can result in signiﬁcant chronic pain, dysfunction and disﬁg-
urement which are difﬁcult to treat, the aim should be
prevention.
There are conﬂicting reports regarding dental implants.
Experimental studies show a positive effect of bisphosphonates
on the bone around implants in experimental animals and hu-
mans. Failure of osteointegration in a patient on bisphospho-
nate therapy has been reported. Current advice is that
placement of implants may be avoided if the patient has seri-
ous bone disease and are on potent doses of the drug. Osteo-
porotic patients on lower doses need a full informed consent
before proceeding with treatment. Patients on bisphosphonate
therapy with existing implants should be regularly monitored.
Increased bone density around the implant may occur. If bone
pain or loss of integrity occurs the superstructure should be re-
moved and the implant left submerged. Bone surgery must be
avoided as the bone is exceedingly dense and avascular necro-
sis may occur.
Dental treatment seems to be a precipitating event in
development of most cases of bisphosphonates-related
osteochemonecrosis. It is therefore imperative that patients
100 Editorialreceiving necessary treatment have their dental status assessed
prior to bisphosphonate therapy. This includes control of den-
tal caries and periodontal disease, avoiding dental implant
placement, using soft liners on dentures, and to recommend
an alternative to tooth extractions for patients with history
of receiving bisphosphonate therapy. This is because with-
drawal of bisphosphonate therapy before major dental proce-
dures does not appear to hasten recovery of osteonecrosis due
to their persistence in bone. In established cases, the primary
goals are palliation and control of osteomyelitis. Progression
of disease can usually be controlled with antibiotics, periodic
surgical debridement of sequestrating bone and wound irriga-
tion. However, these have proven consistently ineffective. Sur-
gical treatment should only be reserved for symptomatic
patients. It is important to make health care professionals
and patients aware of the potential risk of bisphosphonate
treatment. Once the therapy has commenced, regular dental
monitoring of oral health and a preventive approach should
be adopted. Patients should be educated regarding good oral
hygiene practices and to report having come across any symp-
toms. There should be a greater collaboration between oral
health providers, physicians and surgeons alike to minimize
the complications of this therapy, thereby keeping patient mor-
bidity at check. The goal of this approach should be, like else-
where, to harness the intrinsic reparative drive to the judicious
pharmacokinetic intervention aimed at avoiding treatment re-
lated health risks.Further reading
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